VOYAGER THERAPEUTICS INC

VYGR represents Voyager Therapeutics, a clinical-stage biotechnology company focused on developing gene therapies for severe neurological diseases. Its work includes advancing treatments for conditions such as Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS). The company also collaborates with larger pharmaceutical partners to develop and commercialize its gene therapy programs. As a clinical-stage company, its activities center on research and development rather than commercial product sales.

Recent performance for VYGR can be found in the price chart and performance data displayed on this page. That information includes the latest price, daily change, and historical trends over various periods. Stock performance for a clinical-stage biotechnology company like VYGR often reflects trial results, partnership news, and broader sector sentiment. For the most current figures, refer to the live data shown here.

Evaluating VYGR requires methods suited to a clinical-stage biotech with no product revenue. Traditional metrics such as the price-to-earnings ratio are often not meaningful. Instead, investors may consider cash position, pipeline prospects, partnership terms, and potential market opportunities for its gene therapies. Analysts sometimes use discounted cash flow or comparable transaction analysis, though these remain speculative. Current valuation data, such as market capitalization, is available on this page.

Trading outside regular U.S. market hours depends on your brokerage and the availability of extended-hours sessions. Many brokers offer pre-market and after-hours trading for eligible securities, including VYGR, but liquidity can be lower and spreads wider. Confirm with your broker whether VYGR is available for extended-hours trading, as eligibility and session times can vary.

VYGR faces risks common to clinical-stage biotechnology companies. These include the possibility that gene therapy candidates fail in clinical trials, regulatory delays or rejections, and the need for additional capital to fund research. Competition, reliance on collaboration partners, and intellectual property challenges also matter. Because the company may not have commercial products, its stock can be sensitive to trial data, financing news, and changes in industry sentiment.

For VYGR, useful financial metrics include cash and cash equivalents, operating expenses, research and development spending, and net loss, since the company is likely pre-revenue or has limited revenue. Investors may also track collaboration revenue, if any, and the burn rate to gauge how long current funds might last. These figures come from quarterly and annual financial statements. Current data should be verified using the latest VYGR filings or the financial information on this page.